Kawazoe, Akihito
Kuboki, Yasutoshi
Bando, Hideaki
Fukuoka, Shota
Kojima, Takashi
Naito, Yoichi http://orcid.org/0000-0002-8490-9064
Iino, Shuichi
Yodo, Yasuhide
Doi, Toshihiko
Shitara, Kohei
Yoshino, Takayuki
Funding for this research was provided by:
Sumitomo Dainippon Pharma
Article History
Received: 9 October 2019
Accepted: 12 March 2020
First Online: 31 March 2020
Compliance with ethical standards
:
: A.K. received research funding from MSD, Ono Pharmaceutical, Sumitomo Dainippon Pharma and Taiho. Y.K. received research funding from Sumitomo Dainippon Pharma and honoraria from MSD. H.B. received lecture fees from and Eli Lilly Japan and Taiho and research funding from, AstraZeneca, Sysmex and Taiho. S.F. and T.K. have no conflict of interest to declare. Y.N. has served on speakers’ bureau from Chigai Pharma, Eisai, Novartis and Pfizer, and research funding from Roche. S.I. and Y.Y. are employees of Sumitomo Dainippon Pharma. T.D. has held a consulting/advisory role for Abbvie, Amgen, Bayer, Boeringer Ingelheim, Daiichi Sankyo, Kyowa Hakko Kirin, MSD, Novartis, Rakuten Medical, Sumitomo Dainippon Pharma, Taiho, and Takeda and has received research funding from Abbvie, Boeringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa Hakko Kirin, Merck Serono, MSD, Novartis, Pfizer, Sumitomo Dainippon Pharma and Taiho Pharmaceutical. K.S. received personal fees from AbbVie, Astellas Pharma, Bristol Myers Squibb, Eli Lilly, MSD, Ono Pharmaceutical, Novartis, Pfizer, Takeda and Yakult and grants from Astellas Pharma, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Medi Science, MSD, Ono Pharmaceutical, Sumitomo Dainippon Pharma and Taiho Pharmaceutical. T.Y. has received research funding from Chugai Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., GlaxoSmithKline K.K., MSD K.K., Novartis, K.K., Ono Pharmaceutical Co., Ltd., Parexel International Inc., Sanofi K.K. and Sumitomo Dainippon Pharma Co., Ltd.